For the year ending 2025-12-31, AXSM made $638,496K in revenue. -$183,174K in net income. Net profit margin of -28.69%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 638,496 | 381,677 | ||
| Cost of revenue (excluding amortization and depreciation) | 47,478 | 33,303 | ||
| Research and development | 183,279 | 187,077 | ||
| Selling, general and administrative | 570,599 | 411,359 | ||
| Loss (gain) in fair value of contingent consideration | -2,473 | 28,124 | ||
| Intangible asset amortization | 6,375 | 6,392 | ||
| Total operating expenses | 805,258 | 666,255 | ||
| Loss from operations | -166,762 | -280,562 | ||
| Interest expense, net | -6,557 | -6,569 | ||
| Loss on debt extinguishment | -10,385 | - | ||
| Loss before income taxes | -183,704 | -287,131 | ||
| Income tax benefit (expense) | -530 | 85 | ||
| Net loss | -183,174 | -287,216 | ||
| Basic EPS | -3.68 | -5.99 | ||
| Diluted EPS | -3.68 | -5.99 | ||
| Basic Average Shares | 49,747,178 | 47,914,253 | ||
| Diluted Average Shares | 49,747,178 | 47,914,253 | ||
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)